Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy
Montanide ISA-51 enhances anti-tumor immune responses by improving antigen release and facilitating immune cell aggregation and activation, thereby boosting the effectiveness of vaccines against melanoma, glioma, and HPV-related cancers. When combined with TLR agonists or other immunomodulatory agents, Montanide ISA-51 further amplifies the immune response. However, despite its potential, the precise mechanisms underlying its effects in the complex immune environment remain to be fully understood. These insights will accelerate the translation of Montanide ISA-51 into clinical use as an adjuvant for cancer vaccines.
Authors
- Ningshao Xia (ORCID: https://orcid.org/0000-0003-0179-5266)
- Xiuli Zhang (ORCID: https://orcid.org/0000-0001-5280-3049)
- Nan Liu (ORCID: https://orcid.org/0000-0003-2901-3721)
- Ziyi Li (ORCID: https://orcid.org/0000-0003-0947-9137)
- Shaowei Li (ORCID: https://orcid.org/0000-0002-3374-1038)
Institutions
- Xiamen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1080/14760584.2025.2576234
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59